Lantheus today said it appointed Paul Blanchfield as chief commercial officer, effective immediately.
Blanchfield will report to president and CEO Mary Anne Heino.
“With his extensive operational experience and deep expertise in commercializing rare disease products, Paul will be a valuable addition to our executive leadership team as we execute our long-term growth strategy,” Heino said in a news release. “Following the recent appointment of Dr. Istvan Molnar as chief medical officer, the addition of Paul to our team further enhances our exceptional expertise in complex manufacturing, supply chain and commercial excellence. We look forward to working with Paul and the rest of our team as we continue the exciting momentum we have generated as we focus on building sustainable, long-term shareholder value.”
Blanchfield most recently served as the head of the U.S. immunology business at Takeda Pharmaceutical. He has also held a number of leadership roles at Shire and McKinsey & Company.
